乳腺癌蒽环类新辅助化疗疗效与ER、PR、HER2表达的关系

目的探讨乳腺癌蒽环类新辅助化疗疗效与ER、PR、HER2表达的关系。方法乳腺癌患者在接受蒽环类方案新辅助化疗前用免疫组化法检测乳腺癌组织中ER、PR和HER2的表达情况，新辅助化疗3周期结束后进行疗效评价，分析它们之间的关系。结果ER和PR阴性表达组47例，有效率为80．85％；其中PCR率为23．40％。ER和（或）PR阳性表达组43例，有效率为60．47％；其中PCR为6．98％。两组有效率及PER率比较，差异有统计学意义（P〈0．05）。HER2阳性表达组32例，有效率为65．63％；其中PCR率为12．50％。HER2阴性表达组58例，有效率为74．14％；其中PCR率为17．24％。两组有效率及PCR率比较，差异无统计学意义（P〉0．05）。结论激素受体双阴者可能较单阳或双阳者对蒽环类方案化疗的敏感性更高。尤其是激素受体双阴者的PCR率明显高于单阳或双阳者。

The relationship between expression of ER, PR and HER2 in breast cancer patients with the efficaey of anthracycline neoadjuvant chemotherapy

Objective To study the relationship between expression of estrogen receptor（ ER）, progesterone receptor （PR） and HER2 in breast cancer patients with the efficacy of anthracycline neoadjavant chemotherapy. Methods The ER, PR and HER2 expression situation in the patients with breast cancer were examined immunohistochemically before the operation were treated with anthracycline neoadjuvant chemotherapy. And the response was evaluated after 3 circles and the correlation between them was analysed. Results In 47 patients with ER and PR absent, the response rates is 80. 85 % and the PCR rates is 23.40%.In 43 patients with ER or PR positive tumors, the response rates is 60. 47%, and the PCR rates is 6. 98%.Compared the response rates of the two groups and the PCR rates of the two groups, there is significant difference （P 〈 0.05 ）. In 32 patients with HER？, positive expression, the response rate is 65.63% and the PCR rate is 12.50%. In 58 patients with HER2 negative expression, the response rate is 74. 14% and the PCR rate is 17.24%. Compared the response ＇rates of the two groups and the PCR rates of the two groups, there is no significant difference （ P 〉 0. 05 ）. Conclusion Breast cancer with ER and PR absent may be more sensitive to anthracycline neoadjuvant chemotherapy. Especially, the PCR rate of the patients with ER and PR absent is obviously higher than the patients with ER and PR oositive tumors.